Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

Admission to intensive care: A qualitative study of triage and its determinants.

Escher M, Cullati S, Hudelson P, Nendaz M, Ricou B, Perneger T, Dayer P.

Health Serv Res. 2019 Apr;54(2):474-483. doi: 10.1111/1475-6773.13076. Epub 2018 Oct 25.

PMID:
30362106
2.

Locally produced natural conditioners for dewatering of faecal sludge.

Gold M, Dayer P, Faye MC, Clair G, Seck A, Niang S, Morgenroth E, Strande L.

Environ Technol. 2016 Nov;37(21):2802-14. doi: 10.1080/09593330.2016.1165293. Epub 2016 Apr 18.

3.

[Clinical pharmacology of medical cannabinoids in chronic pain].

Ing Lorenzini K, Broers B, Lalive PH, Dayer P, Desmeules J, Piguet V.

Rev Med Suisse. 2015 Jun 24;11(480):1390, 1392-4. Review. French.

PMID:
26267945
4.

Prioritization methodology for the monitoring of active pharmaceutical ingredients in hospital effluents.

Daouk S, Chèvre N, Vernaz N, Bonnabry P, Dayer P, Daali Y, Fleury-Souverain S.

J Environ Manage. 2015 Sep 1;160:324-32. doi: 10.1016/j.jenvman.2015.06.037. Epub 2015 Jul 2.

PMID:
26144564
5.

Drug-related problems identification in general internal medicine: The impact and role of the clinical pharmacist and pharmacologist.

Guignard B, Bonnabry P, Perrier A, Dayer P, Desmeules J, Samer CF.

Eur J Intern Med. 2015 Jul;26(6):399-406. doi: 10.1016/j.ejim.2015.05.012. Epub 2015 Jun 9.

PMID:
26066400
6.

Providing Quality Therapeutics in Switzerland: Role of the Stakeholders and Recent Incentives for Further Improvements.

Besson M, Samer C, Rollason V, Dayer P, Desmeules J.

Clin Ther. 2015 Jul 1;37(7):1588-92. doi: 10.1016/j.clinthera.2015.05.005. Epub 2015 Jun 3.

PMID:
26049714
7.

P-glycoprotein: a clue to vitamin K antagonist stabilization.

Gschwind L, Rollason V, Boehlen F, Rebsamen M, Combescure C, Matthey A, Bonnabry P, Dayer P, Desmeules JA.

Pharmacogenomics. 2015 Jan;16(2):129-36. doi: 10.2217/pgs.14.164.

PMID:
25616099
8.

Doctors' decisions when faced with contradictory patient advance directives and health care proxy opinion: a randomized vignette-based study.

Escher M, Perrier A, Rudaz S, Dayer P, Perneger TV.

J Pain Symptom Manage. 2015 Mar;49(3):637-45. doi: 10.1016/j.jpainsymman.2014.06.012. Epub 2014 Aug 15.

9.

Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: a cost-effectiveness analysis.

Girardin FR, Poncet A, Blondon M, Rollason V, Vernaz N, Chalandon Y, Dayer P, Combescure C.

Lancet Psychiatry. 2014 Jun;1(1):55-62. doi: 10.1016/S2215-0366(14)70245-7. Epub 2014 Jun 4.

PMID:
26360402
10.

Volunteers trained in palliative care at the hospital: an original and dynamic resource.

Delaloye S, Escher M, Luthy C, Piguet V, Dayer P, Cedraschi C.

Palliat Support Care. 2015 Jun;13(3):601-7. doi: 10.1017/S1478951514000169. Epub 2014 Apr 24.

PMID:
24762324
11.

Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.

Bosilkovska M, Samer CF, Déglon J, Rebsamen M, Staub C, Dayer P, Walder B, Desmeules JA, Daali Y.

Clin Pharmacol Ther. 2014 Sep;96(3):349-59. doi: 10.1038/clpt.2014.83. Epub 2014 Apr 10.

12.

Incorporation of flurbiprofen in a 4-drug cytochrome p450 phenotyping cocktail.

Bosilkovska M, Clément M, Dayer P, Desmeules J, Daali Y.

Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):465-6. doi: 10.1111/bcpt.12231. Epub 2014 Apr 25. No abstract available.

13.

Central pain sensitization, COMT Val158Met polymorphism, and emotional factors in fibromyalgia.

Desmeules J, Chabert J, Rebsamen M, Rapiti E, Piguet V, Besson M, Dayer P, Cedraschi C.

J Pain. 2014 Feb;15(2):129-35. doi: 10.1016/j.jpain.2013.10.004. Epub 2013 Oct 20.

PMID:
24342707
14.

Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study.

Girardin FR, Gex-Fabry M, Berney P, Shah D, Gaspoz JM, Dayer P.

Am J Psychiatry. 2013 Dec;170(12):1468-76. doi: 10.1176/appi.ajp.2013.12060860.

PMID:
24306340
15.

Dual reuptake inhibitor milnacipran and spinal pain pathways in fibromyalgia patients: a randomized, double-blind, placebo-controlled trial.

Matthey A, Cedraschi C, Piguet V, Besson M, Chabert J, Daali Y, Courvoisier D, Montagne A, Dayer P, Desmeules JA.

Pain Physician. 2013 Sep-Oct;16(5):E553-62.

16.

Patented drug extension strategies on healthcare spending: a cost-evaluation analysis.

Vernaz N, Haller G, Girardin F, Huttner B, Combescure C, Dayer P, Muscionico D, Salomon JL, Bonnabry P.

PLoS Med. 2013;10(6):e1001460. doi: 10.1371/journal.pmed.1001460. Epub 2013 Jun 4.

17.

Impact of advance directives and a health care proxy on doctors' decisions: a randomized trial.

Escher M, Perneger TV, Rudaz S, Dayer P, Perrier A.

J Pain Symptom Manage. 2014 Jan;47(1):1-11. doi: 10.1016/j.jpainsymman.2013.03.010. Epub 2013 Jun 4.

18.

Evidence of drug-drug interactions through uptake and efflux transport systems in rat hepatocytes: implications for cellular concentrations of competing drugs.

Daali Y, Millet P, Dayer P, Pastor CM.

Drug Metab Dispos. 2013 Aug;41(8):1548-56. doi: 10.1124/dmd.113.051870. Epub 2013 May 24.

PMID:
23708009
19.

Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model.

Gschwind L, Rollason V, Daali Y, Bonnabry P, Dayer P, Desmeules JA.

Basic Clin Pharmacol Toxicol. 2013 Oct;113(4):259-65. doi: 10.1111/bcpt.12084. Epub 2013 Jun 25.

20.

Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.

Gschwind L, Rollason V, Boehlen F, Rebsamen M, Combescure C, Grünenwald M, Matthey A, Bonnabry P, Dayer P, Desmeules JA.

Pharmacogenomics. 2013 May;14(7):745-53. doi: 10.2217/pgs.13.55.

PMID:
23651023
21.

Intraocular penetration of penciclovir after oral administration of famciclovir: a population pharmacokinetic model.

Schenkel F, Csajka C, Baglivo E, Kondo-Oestreicher M, Dayer P, Gex-Fabry M, Daali Y.

J Antimicrob Chemother. 2013 Jul;68(7):1635-41. doi: 10.1093/jac/dkt064. Epub 2013 Mar 28.

PMID:
23539240
22.

Influence of CYP2D6 activity on pre-emptive analgesia by the N-methyl-D-aspartate antagonist dextromethorphan in a randomized controlled trial of acute pain.

Ehret GB, Daali Y, Chabert J, Rebsamen M, Wolff A, Forster A, Moursli F, Fritschy D, Rossier MF, Piguet V, Dayer P, Gex-Fabry M, Desmeules JA.

Pain Physician. 2013 Jan;16(1):45-56.

23.

[Comparison of four drug interaction screening programs].

Ing Lorenzini K, Reutemann B, Samer CF, Guignard B, Bonnabry P, Dayer P, Perrier A, Desmeules J.

Rev Med Suisse. 2012 Oct 17;8(358):1978-82. French.

PMID:
23198652
24.

Antihyperalgesic effect of the GABA(A) ligand clobazam in a neuropathic pain model in mice: a pharmacokinetic-pharmacodynamic study.

Besson M, Daali Y, Di Lio A, Dayer P, Zeilhofer HU, Desmeules J.

Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):192-7. doi: 10.1111/bcpt.12017. Epub 2012 Nov 14.

25.

Identification and weighting of the most critical "real-life" drug-drug interactions with acenocoumarol in a tertiary care hospital.

Gschwind L, Rollason V, Lovis C, Boehlen F, Bonnabry P, Dayer P, Desmeules JA.

Eur J Clin Pharmacol. 2013 Mar;69(3):617-27. doi: 10.1007/s00228-012-1358-7. Epub 2012 Aug 19.

PMID:
22903542
26.

Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers.

Ancrenaz V, Déglon J, Samer C, Staub C, Dayer P, Daali Y, Desmeules J.

Basic Clin Pharmacol Toxicol. 2013 Feb;112(2):132-7. doi: 10.1111/j.1742-7843.2012.00932.x. Epub 2012 Oct 5.

27.

Validation of the simplified UVB model to assess the pharmacodynamics of analgesics in healthy human volunteers.

Ing Lorenzini K, Besson M, Daali Y, Salomon D, Dayer P, Desmeules J.

Chimia (Aarau). 2012;66(5):296-9. doi: 10.2533/chimia.2012.296.

PMID:
22867539
28.

Transcriptional regulation of CYP2C19 and its role in altered enzyme activity.

Uppugunduri CR, Daali Y, Desmeules J, Dayer P, Krajinovic M, Ansari M.

Curr Drug Metab. 2012 Oct;13(8):1196-204. Review.

PMID:
22804232
29.

[Atypical femoral fracture associated with the use of bisphosphonates, an adverse drug reaction not to be missed].

Ing Lorenzinit K, Meier R, Suva D, Dayer P, Desmeules J, Peter R.

Rev Med Suisse. 2012 Jun 6;8(344):1238-42. Review. French.

PMID:
22730621
30.

A simplified method for busulfan monitoring using dried blood spot in combination with liquid chromatography/tandem mass spectrometry.

Ansari M, Uppugunduri CR, Déglon J, Théorêt Y, Versace F, Gumy-Pause F, Ozsahin H, Dayer P, Desmules J, Daali Y.

Rapid Commun Mass Spectrom. 2012 Jun 30;26(12):1437-46. doi: 10.1002/rcm.6241.

PMID:
22592987
31.

The paraoxonase-1 pathway is not a major bioactivation pathway of clopidogrel in vitro.

Ancrenaz V, Desmeules J, James R, Fontana P, Reny JL, Dayer P, Daali Y.

Br J Pharmacol. 2012 Aug;166(8):2362-70. doi: 10.1111/j.1476-5381.2012.01946.x.

32.

Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot.

Daali Y, Samer C, Déglon J, Thomas A, Chabert J, Rebsamen M, Staub C, Dayer P, Desmeules J.

Clin Pharmacol Ther. 2012 Mar;91(3):489-96. doi: 10.1038/clpt.2011.247. Epub 2012 Jan 11.

PMID:
22237256
33.

Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. a minireview.

Ing Lorenzini K, Daali Y, Dayer P, Desmeules J.

Basic Clin Pharmacol Toxicol. 2012 Mar;110(3):219-26. doi: 10.1111/j.1742-7843.2011.00814.x. Epub 2011 Nov 9. Review.

34.

ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia.

L'Huillier AG, Ing Lorenzini K, Crisinel PA, Rebsamen MC, Fluss J, Korff CM, Barbe RP, Siegrist CA, Dayer P, Posfay-Barbe KM, Desmeules JA; H1N1 Pediatric Epidemiology Study Group of Geneva.

Pharmacogenomics. 2011 Oct;12(10):1493-501. doi: 10.2217/pgs.11.91. Epub 2011 Sep 8.

35.

Psychological distress in fibromyalgia patients: a role for catechol-O-methyl-transferase Val158met polymorphism.

Desmeules J, Piguet V, Besson M, Chabert J, Rapiti E, Rebsamen M, Rossier MF, Curtin F, Dayer P, Cedraschi C.

Health Psychol. 2012 Mar;31(2):242-249. doi: 10.1037/a0025223. Epub 2011 Sep 5.

PMID:
21895373
36.

A randomized, controlled trial validates a peripheral supra-additive antihyperalgesic effect of a paracetamol-ketorolac combination.

Ing Lorenzini K, Besson M, Daali Y, Salomon D, Dayer P, Desmeules J.

Basic Clin Pharmacol Toxicol. 2011 Nov;109(5):357-64. doi: 10.1111/j.1742-7843.2011.00733.x. Epub 2011 Jul 6.

37.

Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients.

Daali Y, Ancrenaz V, Bosilkovska M, Dayer P, Desmeules J.

Metabolism. 2011 Nov;60(11):1584-9. doi: 10.1016/j.metabol.2011.03.015. Epub 2011 May 6.

PMID:
21550074
38.

How close are we to individual analgesic adjustment according to a patient's genotype?

Samer CF, Dayer P, Desmeules JA.

Per Med. 2011 May;8(3):289-292. doi: 10.2217/pme.11.13. No abstract available.

39.

Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.

Ancrenaz V, Daali Y, Fontana P, Besson M, Samer C, Dayer P, Desmeules J.

Curr Drug Metab. 2010 Oct;11(8):667-77. Review.

PMID:
20942779
40.

Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite.

Déglon J, Thomas A, Daali Y, Lauer E, Samer C, Desmeules J, Dayer P, Mangin P, Staub C.

J Pharm Biomed Anal. 2011 Jan 25;54(2):359-67. doi: 10.1016/j.jpba.2010.08.032.

PMID:
20864289
41.

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.

Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA.

Br J Pharmacol. 2010 Jun;160(4):919-30. doi: 10.1111/j.1476-5381.2010.00709.x.

42.

The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.

Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA.

Br J Pharmacol. 2010 Jun;160(4):907-18. doi: 10.1111/j.1476-5381.2010.00673.x.

43.

Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital.

Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R.

Drug Saf. 2009;32(9):775-85. doi: 10.2165/00002018-200932090-00002.

PMID:
19670917
44.

P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone.

Kanaan M, Daali Y, Dayer P, Desmeules J.

Fundam Clin Pharmacol. 2009 Oct;23(5):543-8. doi: 10.1111/j.1472-8206.2009.00724.x. Epub 2009 Jul 28.

PMID:
19656202
45.

Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein.

Kanaan M, Daali Y, Dayer P, Desmeules J.

Basic Clin Pharmacol Toxicol. 2009 Sep;105(3):199-206. doi: 10.1111/j.1742-7843.2009.00428.x. Epub 2009 May 26.

46.

[Social marketing: applying commercial strategies to the prevention of nosocomial infections].

Sax H, Longtin Y, Alvarez-Ceyssat R, Bonfillon C, Cavallero S, Dayer P, Ginet C, Herrault P.

Rev Med Suisse. 2009 Apr 1;5(197):735-8. French.

PMID:
19492518
47.

Influence of ABCB1 gene polymorphisms and P-glycoprotein activity on cyclosporine pharmacokinetics in peripheral blood mononuclear cells in healthy volunteers.

Ansermot N, Rebsamen M, Chabert J, Fathi M, Gex-Fabry M, Daali Y, Besson M, Rossier M, Rudaz S, Hochstrasser D, Dayer P, Desmeules J.

Drug Metab Lett. 2008 Apr;2(2):76-82.

PMID:
19356075
48.

Two-dimensional liquid chromatography-ion trap mass spectrometry for the simultaneous determination of ketorolac enantiomers and paracetamol in human plasma: application to a pharmacokinetic study.

Ing-Lorenzini KR, Desmeules JA, Besson M, Veuthey JL, Dayer P, Daali Y.

J Chromatogr A. 2009 May 1;1216(18):3851-6. doi: 10.1016/j.chroma.2009.02.071. Epub 2009 Mar 3.

PMID:
19281996
49.

[Off-label prescribing].

Blondon K, Desmeules J, Vogt-Ferrier N, Besson M, Kondo-Oestreicher M, Dayer P.

Rev Med Suisse. 2008 Jul 16;4(165):1661-5. Review. French.

PMID:
18767292
50.

[Those words don't speak...Aprotinin and erythropoiesis stimulant agents, therapeutic use and adverse effects].

Biollaz J, Dayer P.

Rev Med Suisse. 2008 Jul 16;4(165):1635-6. French. No abstract available.

PMID:
18767288

Supplemental Content

Support Center